Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section
Photo of Shitalben Radheshyambhai Patel

Shitalben Radheshyambhai Patel

Assoiate Director for Research Laboratory Operations/Sr. Research Specialist, Pharmacy Practice

Contact Information

833 S. Wood Street (886)
112 E
Chicago, IL 60612

Phone: (312) 413-4293

Fax: (312) 996-0379

Intellectual Contributions

Journal Article

  • Stevenson J, Reilly J, Harris M, Patel, SR , Weiden P, Prasad K, Badner J, Nimgaonkar V, Keshavan M, Sweeney J, others . "Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes". Translational psychiatry. 2016;6(2):e739.
  • Mansour IN, Bress AP, Groo VL, Ismail S, Wu G, Patel SR, Duarte JD, Kittles RA, Stamos TD, Cavallari LH. "Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure". Journal of cardiac failure. 2016;22(9):692–699.
  • Nagai R, Ohara M, Cavallari LH, Drozda K, Patel SR, Nutescu EA, Perera MA, Hernandez W, Kaneko N, Hibiya M, others . "Factors influencing pharmacokinetics of warfarin in African–Americans: implications for pharmacogenetic dosing algorithms". Pharmacogenomics. 2015;16(3):217–225.
  • Drozda K, Lee Y, Patel, SR , Lee JC, Pugach O, Duarte J, Nutescu E, Cavallari L. "Genetic Associations With Warfarin Response In Patients Receiving Genotype-guided Dosing". Clinical Pharmacology & Therapeutics. 2015;97:S26.
  • Bishop JR, Reilly JL, Harris MS, Patel SR, Kittles R, Badner JA, Prasad KM, Nimgaonkar VL, Keshavan MS, Sweeney JA. "Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia". Psychopharmacology. 2015;232(1):145–154.
  • Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, Cavallari LH. "Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans". Pharmacogenetics and genomics. 2015;25(2):73.
  • Katz AC, Sarapas C, Bishop JR, Patel SR, Shankman SA. "The mediating effect of prefrontal asymmetry on the relationship between the COMT Val158Met SNP and trait consummatory positive affect". Cognition and Emotion. 2015;29(5):867–881.
  • Drozda K, Patel SR, Nutescu EA, Cavallari L. "Addition of Cyp2c9* 5,* 6,* 8,* 11 and rs12777823 genotypes into an existing warfarin dosing algorithm improves algorithm performance for African Americans.". Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy. 2014;34(10):e220–e221.
  • Lencer R, Bishop JR, Harris MS, Reilly JL, Patel SR, Kittles R, Prasad KM, Nimgaonkar VL, Keshavan MS, Sweeney JA. "Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis". European archives of psychiatry and clinical neuroscience. 2014;264(4):345–355.
  • Drozda K, Wong S, Patel SR, Nutescu EA, Cavallari L. "Effects Of African-specific Genetic Variation On Performance Of Warfarin Pharmacogenetic Dosing Algorithms.". Clinical Pharmacology & Therapeutics. 2014;95(1):S11.
  • Hernandez W, Gamazon ER, Aquino-Michaels K, Patel SR, O’Brien TJ, Harralson AF, Kittles RA, Barbour A, Tuck M, McIntosh SD, others . "Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans". The pharmacogenomics journal. 2014;14(3):223–228.
  • Daneshjou R, Gamazon ER, Burkley B, Cavallari LH, Johnson JA, Klein TE, Limdi N, Hillenmeyer S, Percha B, Karczewski KJ, others . "Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans". Blood. 2014;124(14):2298–2305.
  • Hernandez W, Gamazon E, Aquino-Michaels K, Patel SR, O’brien T, Harralson A, Kittles R, Barbour A, Tuck M, Mcintosh S, others . "Liver Eqtls For Warfarin Dose Response Genes Reveal Susceptibility To Venous Thromboembolism Among African Americans.". Clinical Pharmacology & Therapeutics. 2014;95(1):S60.
  • Hernandez W, Aquino-Michaels K, Drozda K, Patel S, , Jeong H, Takahashi H, Cavallari LH, Perera MA. . "Novel SNP in CYP2C9 is associated with changes in warfarin clearance and CYP2C9 expression levels in African Americans.". Translational Research. 2014;.
  • 10. Mansour I, Ismail S, Bress A, Groo V , , Patel S, Gheith H, Stamos T, , L C. "PIIINP Predicts Mortality in African American Patients with Heart Failure.". Journal of Cardiac Failure. 2014;.
  • Patel SR, Langaee TY, Wong SS, Cavallari LH. "Pyrosequencing of the CYP2C9-1766T> C polymorphism as a means of detecting the CYP2C9* 8 allele". Pharmacogenomics. 2014;15(13):1717–1722.
  • DiDomenico RJ, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman J. "Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure.". Pharmacotherapy. 2014;34(11):1121-31. doi:10.1002/phar.1480.
  • Hernandez W, Perera M, Gamazon E, Perry K, Aquino-Michaels K, Patel SR, O’brien T, Harralson A, Nicolae D, Cavallari L. "A Novel Pharmacogenomics Dosing Algorithm For African Americans Taking Warfarin: Able To Predict Where Iwpc’s Algorithm Cannot.". Clinical Pharmacology & Therapeutics. 2013;93:S12.
  • Drozda K, Labinov Y, Jiang R, Thomas MR, Wong SS, Patel SR, Nutescu EA, Cavallari LH. "A pharmacogenetics service experience for pharmacy students, residents, and fellows". American journal of pharmaceutical education. 2013;77(8):175.
  • Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo VL, Progar K, Shah E, Stamos TD, Wing C, Garcia JG, Kittles R, Cavallari LH. "Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure". PLoS One. 2013;8(7):e71268.
  • Goncharenko A, Kadlec A, Bress A, Patel SR, Vardeny O, Gross V, Stamos T, Sweitzer NK, Cavallari L. "Epithelial Sodium Channel Genotype Is Associated with Elevated Potassium among Patients with Heart Failure Taking a Mineralocorticoid Receptor Antagonist". Journal of Cardiac Failure. 2013;19(8):S56.
  • Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, others . "Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study". The Lancet. 2013;382(9894):790–796.
  • Shahin MH, Cavallari LH, Perera MA, Khalifa SI, Misher A, Langaee T, Patel SR, Perry K, Meltzer DO, McLeod HL, others . "VKORC1 Asp36Tyr geographic distribution and its impact on warfarin dose requirements in Egyptians". Thrombosis and haemostasis. 2013;109(6):1045.
  • Cavallari LH, Vaynshteyn D, Freeman KM, Wang D, Perera MA, Takahashi H, Drozda K, Patel SR, Jeong H. "CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.". Pharmacogenetics and genomics. 2013;23(4):228-31. doi:10.1097/FPC.0b013e32835e95c7.
  • Cavallari LH, Perera M, Wadelius M, Deloukas P, Taube G, Patel SR, Aquino-Michaels K, Viana MA, Shapiro NL, Nutescu EA. "Association of the GGCX (CAA) 16/17 repeat polymorphism with higher warfarin dose requirements in African Americans". Pharmacogenetics and genomics. 2012;22(2):152.
  • Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH. "Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic–Americans and African–Americans". Pharmacogenomics. 2012;13(16):1925–1935.
  • Bishop JR, Chae SS, Patel SR, Moline J, Ellingrod VL. "Pharmacogenetics of glutamate system genes and SSRI-associated sexual dysfunction". Psychiatry research. 2012;199(1):74–76.
  • Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Cavallari LH. "Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.". Clinical pharmacology and therapeutics. 2012;91(4):660-5. doi:10.1038/clpt.2011.269.
  • Cavallari LH, Butler C, Langaee TY, Wardak N, Patel SR, Viana MA, Shapiro NL, Nutescu EA. "Association of Apolipoprotein E Genotype with Duration of Time to Achieve a Stable Warfarin Dose in African-American Patients". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2011;31(8):785–792.
  • Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu EA, Viana MA. "Pharmacogenomics of warfarin dose requirements in Hispanics". Blood Cells, Molecules, and Diseases. 2011;46(2):147–150.
  • Perera M, Gamazon E, Cavallari L, Patel, SR , Poindexter S, Kittles RA, Nicolae D, Cox N. "The Missing Association: Sequencing-Based Discovery of Novel SNPs in VKORC1 and CYP2C9 That Affect Warfarin Dose in African Americans". Clinical Pharmacology & Therapeutics. 2011;89(3):408–415.
  • Voora D, Koboldt D, King C, Lenzini P, Eby C, Porche-Sorbet R, Deych E, Crankshaw M, Milligan P, McLeod H, others . "A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans". Clinical Pharmacology & Therapeutics. 2010;87(4):445–451.
  • Cavallari LH, Groo VL, Viana MA, Dai Y, Patel SR, Stamos TD. "Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2010;30(1):1–9.
  • Cavallari L, Langaee T, Momary K, Shapiro NL, Nutescu E, Coty W, Viana M, Patel, SR , Johnson J. "Genetic and clinical predictors of warfarin dose requirements in African Americans.". Clinical Pharmacology & Therapeutics. 2010;87(4).
  • Cavallari LH, Patel SR, Blekhman Y, Groo VL, Stamos TD. "NPPA Genotype Is Associated With Aldosterone Breakthrough in Heart Failure". Journal of Cardiac Failure. 2010;16(8):S38.
  • Lindley K, Limdi N, Cavallari LH, Perera M, Lenzini P, Johnson J, Wu A, Ridker P, Patel SR, King C, others . "Warfarin Dosing in Patients with the CYP2C9* 5 Variant". Circulation. 2010;122(Suppl 21):A16860–A16860.
  • Shord SS, Patel SR. "Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines". Journal of Experimental & Clinical Cancer Research. 2009;28(1):76.
  • Cavallari LH, Aston JL, Momary KM, Shapiro NL, Patel SR, Nutescu EA. "Predictors of unstable anticoagulation in African Americans". Journal of thrombosis and thrombolysis. 2009;27(4):430–437.
  • Shord SS, Cavallari LH, Gao W, Jeong H, Deyo KL, Patel SR, Camp JR, Labott SM, Molokie RE. "The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.". European journal of clinical pharmacology. 2009;65(7):651-8. doi:10.1007/s00228-009-0646-3.
  • Shord S, Cavallari L, Viana M, Momary K, Neceskas J, Molokie R, Deyo KL, Patel, SR . "Cytochrome P450 2C9 mediated metabolism in people with and without cancer.". International journal of clinical pharmacology and therapeutics. 2008;46(7):365–374.

Conference Proceeding

  • Hernandez W, Aquino-Michaels K, Perera M, Patel SR, Jeong H, Cavallari L, Takahashi H ed. "ASSOCIATION OF CYP2C9 AND VKORC1 SNPS ON S-WARFARIN CLEARANCE IN AFRICAN AMERICANS" . . 2014.
  • Bishop JR, Reilly JL, Harris MS, Patel SR, Kittles R, Badner JA, Prasad K, Nimgaonkar VL, Keshavan M, Sweeney JA ed. "Pharmacogenomics of the Type-3 Metabotropic Glutamate Receptor (GRM3) Gene and Antipsychotic Treatment Changes in Spatial Working Memory and Clinical Symptoms in Schizophrenia" . . 2014.

Book Chapter

  • Duarte JD, Abbasi T, Patel SR, Desai AA, Wade MS, Cavallari LH, Garcia JG, Machado RF. "Variation In Inducible Nitric Oxide Synthase Is Associated With Increased Severity Of Pulmonary Hypertension In Patients With Diastolic Dysfunction". B29. DIAGNOSTIC AND PROGNOSTIC EVALUATION OF PULMONARY VASCULAR DISEASE. American Thoracic Society; 2013: A2554–A2554